Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.
Alder, based in a suburb of Seattle, has a monoclonal antibody that it has investigated as a treatment for migraine and is under FDA review, with the agency expected to decide on its approval in February of next year. Shares of Alder were up 83 percent on the news.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Ossianix, an early stage biopharmaceutical startup that utilizes shark antibodies as a model for drugs to treat central nervous system disorders, has received a strategic investment from Danish pharmaceutical company H Lundbeck. The investment amount was not disclosed, but Dr. Frank Walsh, cofounder and CEO of Ossianix, said it would be enough to fund the […]
Orasi Medical Inc., a University of Minnesota-bred software startup that is developing software designed to help pharmaceuticals makers speed the development of drugs targeting neurological diseases, like Alzheimer's, has raised $1.8 million from the sale of equity. Overall, the company hopes to raise $2.6 million by December.
Orasi Medical Inc. said Danish drugmaker H. Lundbeck A/S will use its software to test experimental drug compounds on the human brain. Spun out of the University of Minnesota, Orasi has developed technology that can help drug firms determine if their therapies are working by comparing novel brain scans of patients with neurological diseases to […]